Dexmedetomidine for Laryngeal Mask Airway Insertion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01852539|
Recruitment Status : Completed
First Posted : May 13, 2013
Last Update Posted : April 22, 2014
|Condition or disease||Intervention/treatment||Phase|
|Drug Usage||Drug: dexmedetomidine Drug: propofol Device: laryngeal mask airway (LMA)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Optimal Dose of Dexmedetomidine for Laryngeal Mask Airway Insertion During Propofol Induction|
|Study Start Date :||July 2013|
|Actual Primary Completion Date :||August 2013|
|Actual Study Completion Date :||August 2013|
After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
Other Name: precedex
Propofol 2.0 mg/kg was administrated
Other Name: 2% fresofol
Device: laryngeal mask airway (LMA)
The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
- successful insertion of LMA [ Time Frame: from baseline to 2 min after insertion of LMA (participants will be followed for the duration of anesthetic induction, an expected average of 10 min). ]the response of patients to the insertion of LMA (classified as either 'movement' or 'no movement') during infusion of dexmedetomidine and propofol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01852539
|Korea, Republic of|
|Ajou University School of Medicine|
|Suwon, Korea, Republic of, 443-721|
|Study Director:||Jong Yeop Kim, MD||Ajou University School of Medicine|